Patent · US Expired

Arylsulfonylamino hydroxamic acid derivatives

US6153609A · kind A · utility

19Cited by
2References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 16, 1999
Grant dateNov 28, 2000
Priority date
Expiry dateFeb 16, 2019

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C2602/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.